A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Trial Profile

A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs CDX 1401 (Primary) ; Poly ICLC; Resiquimod
  • Indications Advanced breast cancer; Bladder cancer; Malignant melanoma; Myeloma; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Oct 2012 Positive results were presented at the Annual Meeting of the Society for Immunotherapy in October 2012, and were reported in a Celldex Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top